References 8. Jonkman K, Duma A, Olofsen E, Henthorn T, Velzen M van, Mooren R, al. et. Pharmacokinetics and bioavailability of inhaled esketamine in healthy volunteers. Anesthesiology. 2017; 127: 675–683 doi: 10.1097/ALN.0000000000001798. 9. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, RoyByrne PP. Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology. 1998; 88: 82–88 doi: 10.1097/00000542-199801000-00015. 10. Kamp J, Jonkman K, Velzen M van, Aarts L, Niesters M, Dahan A, al. et. Pharmacokinetics of ketamine and its major metabolites norketamine, hydroxynorketamine and dehydronorketamine: a model-based analysis. Br J Anaesth. 2020; 125: 750–761 doi: 10.1016/j.bja.2020.06.067. 11. Kamp J, Olofsen E, Henthorn T, Velzen M van, Niesters M, Dahan A. Ketamine pharmacokinetics. Anesthesiology. 2020; 133: 1192–1213 doi: 10.1097/ALN.0000000000003577. 12. Zanos P, Moadell R, Morris PJ, Riggs LM, Highland JN, Georgiou P, al. et. Mechanism of ketamine action as antidepressant. Mol Psychiatry. 2018; 23: 801–811 doi: 10.1038/mp.2017.255. 13. Adams JDJ, Baillie TA, Trevor AJ, Castagnoli N. Studies on the biotransformation of ketamine. 1-Identification of metabolites produced in vitro from rat liver microsomal preparations. Biomed Mass Spectrom. 1981; 8: 527–538 doi: 10.1002/bms.1200081103. 14. Weiss M, Siegmund W. Pharmacokinetic modeling of ketamine enantiomers and their metabolites after administration of prolonged-release ketamine with emphasis on 2,6-hydroxynorketamines. Clin Pharmacol Drug Develop. 2022; 11: 194–206 doi: 10.1002/cpdd.993. 15. Vondracek M, Xi Z, Larsson P, Baker V, Mace K, Pfeifer A, al. et. Cytochrome P450 expression and related metabolism in human buccal mucosa. Carcinogenesis. 2001; 22: 481–488 doi: 10.1093/carcin/22.3.481. 16. Herwaarden AE van, Wagenaar E, Kruijssen CM van der, Waterschoot RA van, Smit JW, Song JY, al. et. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest. 2007; 117: 3583–3592 doi: 10.1172/JCI33435. 38
RkJQdWJsaXNoZXIy MTk4NDMw